Bipolar Disorder in Social Media: An Examination of Instagram's Role in Disseminating Accurate Information.

Introduction Bipolar disorder is a chronic and recurring condition marked by fluctuations in both energy and mood that can be debilitating to individuals without treatment. While physicians clinically diagnose the condition, patients frequently seek information from alternate channels. Social media platforms, such as Instagram, have facilitated more convenient access to supplementary information about bipolar disorder. Nevertheless, there is apprehension regarding the accuracy of publicly disseminated information through these platforms. The aim of this study is to evaluate the accuracy and dependability of information about Bipolar disorder found on the social media platform, Instagram. Methodology A cross-sectional observational study was conducted by gathering data from Instagram posts linked with popular bipolar disorder hashtags. To evaluate the credibility of the chosen entries, numerical ratings were assigned to each post using the established measurement scales of the Global Quality Score and Reliability Score. Results After analyzing 196 Instagram entries about Bipolar Disorder that fulfilled inclusion criteria, the study revealed that 70.4% (n=138) of these posts were shared by individuals diagnosed with bipolar disorder. Among the content posted by these individuals, a statistically significant global quality score of 2 and a reliability score of 1 were observed. Conclusions Verified medical information of superior global quality should be shared on social media platforms by accountable parties. Individuals with further inquiries about medical knowledge should be advised to reach out to local physicians.

Breaking Barriers: Investigating Gender Representation in the First Authors of Cardiovascular Disease and Artificial Intelligence Publications.

Introduction Artificial intelligence (AI) and cardiovascular diseases have resulted in significant advancements in healthcare and medical research. This study focused on examining the gender equality ratio of first authors in "artificial intelligence and cardiovascular disease" articles from 2005 to 2022. It is critical to investigate gender representation in this dynamic subject given the growing usage of AI in cardiovascular medicine. Aims The aim of this study is to visualize the changing face of gender equality within the field of artificial intelligence (AI) and cardiovascular diseases by examining the gender distribution of the first authors' published articles from 2005 to 2022, providing important insights into disparities in gender and the potential for fostering inclusivity and diversity in the scientific community. Methodology All academic articles published from 2005 to 2022 were reviewed. The gender of the first author of each study was recorded. Since there were so few articles available for five months in 2023, they were excluded. The research was subsequently categorized based on the gender, ethnicity, and country of origin of the first authors. Results With a value of 0.54, the overall gender ratio favored male authors (275) over female authors (149). In 2022, female first authors had the most publications (59), while male first authors contributed 113 articles. Predictions for 2027 showed a significant increase in the number of publications on this topic by male authors (950) and female authors (580). A gradual increase in the number of female first authors was observed over this period, although their representation remained lower compared to male first authors. Conclusions In the first authorship, our analysis found a gender gap, with male authors predominating. Females' engagement must be encouraged if academic gender equality is to be achieved. Female researchers are empowered by creating an inclusive atmosphere through mentorship and regulatory changes. For knowledge to advance fairly, collaboration is essential.

A Rationally Designed Bimetallic Platinum (II)-Ferrocene Antitumor Agent Induces Non-Apoptotic Cell Death and Exerts in Vivo Efficacy.

Despite phenomenal clinical success, the efficacy of platinum anticancer drugs is often compromised due to inherent and acquired drug resistant phenotypes in cancers. To circumvent this issue, we designed two heterobimetallic platinum (II)-ferrocene hybrids that display multi-pronged anticancer action. In cancer cells, our best compound, 2, platinates DNA, produces reactive oxygen species, and has nucleus, mitochondria, and endoplasmic reticulum as potential targets. The multi-modal mechanism of action of these hybrid agents lead to non-apoptotic cell death induction which enables circumventing apoptosis resistance and significant improvement in platinum cross resistance profile. Finally, in addition to describing detail mechanistic insights, we also assessed its stability in plasma and demonstrate anticancer efficacy in an in vivo A2780 xenograft model. Strikingly, compared to oxaliplatin, our compound displays better tolerability, safety profile and efficacy in vivo.